Antiparkinson therapeutic potencies correlate with their affinities at dopamine D2High receptors

Synapse

Volumn 61, Issue 12, 2007, Pages 1013-1018

  Seeman, Philip ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

3H domperidone; Dopamine D2 receptor; High affinity state of D2; N propylnorapomorphine; Parkinson's disease

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ANTIPARKINSON AGENT; APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; DOMPERIDONE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; LERGOTRILE; PERGOLIDE; PERGOLIDE MESILATE; PNU 142799; PRAMIPEXOLE; PROPYLNORAPOMORPHINE; QUINAGOLIDE; QUINPIROLE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BINDING COMPETITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORPUS STRIATUM; CORRELATION ANALYSIS; DRUG POTENCY; DRUG RECEPTOR BINDING; MOUSE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RECEPTOR AFFINITY;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; ANIMALS; ANTIPARKINSON AGENTS; APOMORPHINE; BINDING, COMPETITIVE; CORPUS STRIATUM; DOMPERIDONE; DOPAMINE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; OXAZINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; STATISTICS AS TOPIC; TRITIUM;

EID: 37249075040     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20453     Document Type: Article

References (35)

1. Cheng Y, Prusoff WH. 1973. Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (150) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
2. Coleman RJ, Lange KW, Quinn NP, Loper AE, Bondi JV, Hichens M, Stahl SM, Marsden CD. 1989. The antiparkinsonian actions and pharmacokinetics of transdermal (+)-4-propyl-9-hydroxynaphthoxazine (+PHNO): Preliminary results. Mov Disord 4:129-138.
3. De Keyser J, De Backer JP, Wilczak N, Herroelen L. 1995. Dopamine agonists used in the treatment of Parkinson's disease and their selectivity for the D1, D2, and D3 dopamine receptors in human striatum. Prog Neuropsychopharmacol Biol Psychiatry 19:1147-1154.
4. Durif F, Jeanneau E, Serre-Debeauvais F, Deffond D, Eschalier A, Tournilhac M. 1991. Relation between plasma concentration and clinical efficacy after sublingual single dose apomorphine in Parkinson's disease. Eur J Clin Pharmacol 41:493-494.
5. Foley P, Gerlach M, Double KL, Riederer P. 2004. Dopamine receptor agonists in the therapy of Parkinson's disease. J Neural Transm 111:1375-1446.
6. Freedman SB, Patel S, Marwood R, Emms F, Seabrook GR, Knowles MR, McAllister G. 1994. Expression and pharmacological characterization of the human D3 dopamine receptor. J Pharmacol Exp Ther 268:417-426.
7. Friis ML, Johnsen T, Larsen NE, Hvidberg EF, Pakkenberg H. 1980. Bromocriptine concentration in saliva plasma after long-term treatment of patients with Parkinson's disease. Eur J Clin Pharmacol 18:171-174.
8. George SR, Watanabe M, Di Paolo T, Falardeau P, Labrie F, Seeman P. 1985. The functional state of the dopamine receptor in the anterior pituitary is in the high-affinity form. Endocrinology 117:690-697.
9. Gerlach M, Double K, Arzberger T, Leblhuber F, Tatschner T, Riederer P. 2003. Dopamine receptor agonists in current clinical use: Comparative dopamine receptor binding profiles defined in the human striatum. J Neural Transm 110:1119-1127.
10. 3 mediated? Parkinsonism Relat Disord 7:231-234.
11. Holloway RG, Shoulson I, Fahn S, et al. 2004. Pramipexole vs Levodopa as initial treatment for Parkinson disease: A 4-year randomized controlled trial. Arch Neurol 61:1044-1053 (correction in Arch Neurol 2005; 62:430).
12. Hoover RK, Kukulka MJ, Cole KC, Velagaleti PR, Ronsen B, Bopp BA. 2004. Plasma protein binding and whole blood distribution of apomorphine in plasma and blood from human, dog, rat and mouse. Columbia, MO: Analytical BioChemistry Laboratories, Inc. Google.
13. Jenner P. 2003. Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson's disease. Curr Opin Neurol 16 (Suppl 1):S3-S7.
14. Lahti RA, Figur LM, Piercey MF, Ruppel PL, Evans DL. 1992. Intrinsic activity determinations at the dopamine D2 guanine nucleotide-binding protein-coupled receptor: Utilization of receptor state binding affinities. Mol Pharmacol 42:432-438.
15. Lee T, Seeman P, Rajput A, Farley IJ, Hornykiewicz O. 1978. Receptor basis for dopaminergic supersensitivity in Parkinson's disease. Nature 273:59-61.
16. 3H]raclopride. Proc Natl Acad Sci USA 86:6412-6416.
17. McDonald WM, Sibley DR, Kilpatrick BF, Caron MG. 1984. Dopaminergic inhibition of adenylate cyclase correlates with high affinity agonist binding to anterior pituitary D2 dopamine receptors. Mol Cell Endocrinol 36:201-209.
18. Mierau J, Schneider FJ, Ensinger HA, Chio CL, Lajiness ME, Huff RM. 1995. Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. Eur J Pharmacol 290:29-36.
19. Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A. 2002. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 303:791-804.
20. Miyagi M, Itoh F, Taya F, Arai N, Isaji M, Kojima M, Ujiie A. 1996. Dopamine receptor affinities in vitro and stereotypic activities in vivo of cabergoline in rats. Biol Pharm Bull 19:1210-1213.
21. 11C]-(+)-PHNO is a D3 receptor preferring agonist in vivo. Synapse 60:485-495.
22. 2-adrenoceptor. J Pharmacol Exp Ther 303:805-814.
23. Pearce RKB, Banerji T, Jenner P, Marsden CD. 2004. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Mov Disord 13:234-241.
24. Seeman P, Van Tol HHM. 1995. Deriving the therapeutic concentrations for clozapine and haloperidol: The apparent dissociation constant of a neuroleptic at the dopamine D2 or D4 receptor varies with the affinity of the competing radioligand. Eur J Pharmacol 291:59-66.
25. 3H-spiperone depend on tissue concentration: Analysis and examples. J Neurochem 43:221-235.
26. 2 receptor binding sites for agonists: A tetrahedral model. Mol Pharmacol 28:391-399.
27. 3H]spiperone in isotonic medium: Implications for human positron emission tomography. Synapse 49;209-215.
28. High receptors. Synapse 58:122-128.
29. High dopamine receptors. Synapse 60:319-346.
30. Seeman P, Wilson A, Gmeiner P, Kapur S. 2006b. Dopamine D2 and D3 receptors in human putamen, caudate nucleus, and globus pallidus. Synapse 60:205-211.
31. 3H](+)PHNO. Synapse 61:263-267.
32. Seeman P, Ko F, Jack E, Greenstein R, Dean B. 2007b. Consistent with dopamine supersensitivity, RGS9 expression is diminished in the amphetamine-treated animal model of schizophrenia and in post-mortem schizophrenia brain. Synapse 61:303-309.
33. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. 2000. A five-year study of the incidence of dyskinesia in patients with Parkinson's disease who were treated with ropinirole or levodopa. 056 Study group. New Engl J Med 342:1484-1491.
34. Rascol O, Nutt JG, Blin O, Goetz CG, Trugman JM, Soubrouillard C, Carter JH, Currie LJ, Fabre N, Thalamas C, Giardina WW, Wright S. 2001. Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease. Arch Neurol 58:249-254.
35. Vermeulen RJ, Drukarch B, Sahadat MC, Goosen C, Wolters EC, Stoof JC. 1994. The dopamine D1 agonist SKF 81297 and the dopamine D2 agonist LY 171555 act synergistically to stimulate motor behavior of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-lesioned parkinsonian rhesus monkeys. Mov Disord 9:664-672.